About the Company
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FREQ News
Frequency Therapeutics Inc.
Here's what could happen next to Starbucks shares.
Korro Bio Inc (KRRO)
On Thursday, H.C. Wainwright adjusted its outlook on Korro Bio Inc. (NASDAQ:KRRO), increasing the stock's price target to $115 from the previous $100, while reaffirming a Buy ...
XyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory Angina
XyloCor Therapeutics, Inc. recently revealed the final results from the Phase 2 segment of its EXACT clinical trial at the ...
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
where he was Director of Audiology and Harvard Medical School Faculty in the Department of Otolaryngology-Head and Neck Surgery Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage ...
One Stop Systems Inc (OSS)
Wasatch Advisors increased stake in Frequency Therapeutics, Inc. ByInvesting.com • Oct 02, 2020 On the 30th of September, Wasatch Advisors bought 2.2 million Frequency Therapeutics, Inc. (FREQ ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript May ... of AXS-12 in narcolepsy achieved its primary ...
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Revenue: Reported $4.2 million for Q1 2024, up from $5.2 million in Q1 2023, exceeding the estimated $3.56 million. Net Loss: Increased to $26.4 million in Q1 2024 from $22.5 million in Q1 2023, with ...
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe ...
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growthTotal revenue for Q1 2024 of $63.5 ...
Heron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology ... termination costs that are not related to acquisitions. The amount and/or frequency of these ...
Buy Rating for BioCryst’s Orladeyo: Poised for Pediatric Market Growth and Continued HAE Market Penetration
H.C. Wainwright analyst Andrew Fein has reiterated their bullish stance on BCRX stock, giving a Buy rating today. Andrew Fein has given his ...
Q1 2024 Axsome Therapeutics Inc Earnings Call
Herriot Tabuteau; Chairman of the Board, President, Chief Executive Officer, Founder; Axsome Therapeutics Inc Nick Pizzie ... achieved this primary endpoint and significantly reduced the frequency of ...
Loading the latest forecasts...